Chronic Inflammatory Response Syndrome (CIRS) is a complex, multi-system illness that occurs when the body's immune system remains stuck in a chronic inflammatory state after exposure to biotoxins—most commonly mold spores and mycotoxins found in water-damaged buildings. First identified and researched by Dr. Ritchie Shoemaker, CIRS affects approximately 24% of the population who have a genetic susceptibility that prevents their immune system from properly recognizing and eliminating biotoxins.
Unlike a simple allergic reaction to mold, CIRS involves a cascade of inflammatory responses that affect multiple organ systems simultaneously. People with CIRS often spend years seeking answers, visiting multiple specialists for seemingly unrelated symptoms, without realizing their home or workplace environment is the root cause. The condition can be debilitating, affecting cognitive function, energy levels, hormonal balance, and overall quality of life.
Understanding CIRS is critical because conventional medical approaches often miss the diagnosis entirely, leaving patients to suffer unnecessarily when effective treatment protocols exist. Recovery requires both proper medical intervention and complete elimination of ongoing biotoxin exposure.
What Causes CIRS and Who's at Risk
CIRS develops when genetically susceptible individuals are exposed to water-damaged buildings containing a mixture of biotoxins including mold spores, mycotoxins, bacterial endotoxins, actinomycetes, and beta-glucans. Approximately 24% of the population carries HLA (Human Leukocyte Antigen) gene variants that prevent their immune system from properly tagging biotoxins for removal, causing these toxins to recirculate indefinitely and trigger continuous inflammatory responses.
The most common HLA susceptibility types include:
- HLA-DR 11-3-52B (also called "dreaded")— most susceptible, associated with severe multi-susceptibility
- HLA-DR 4-3-53 — mold-susceptible with potential for severe illness
- HLA-DR 7-2-53 — associated with chronic Lyme disease susceptibility
- HLA-DR 1-5 — lower mold susceptibility but higher risk for other biotoxin illnesses
Exposure to water-damaged buildings is the trigger, but not everyone in the same environment develops CIRS. Those with susceptible genetics cannot produce antibodies against the biotoxins, so their innate immune system remains in constant activation mode. The longer the exposure continues, the more severe the inflammatory cascade becomes, affecting everything from hormone production to visual contrast sensitivity.
Risk factors that increase CIRS severity include previous concussions or traumatic brain injuries, chronic stress, multiple chemical sensitivities, pre-existing autoimmune conditions, and history of Lyme disease or other tick-borne infections.
Recognizing CIRS Symptoms Across Body Systems
CIRS is characterized by multi-system symptoms that often seem unrelated, making diagnosis challenging. The Shoemaker protocol identifies 37 symptoms clustered into 13 categories, and diagnosis requires symptoms from at least 8 of these clusters.
Neurological and Cognitive Symptoms:
- Brain fog, difficulty concentrating, and memory problems (short-term memory particularly affected)
- Confusion, disorientation, and difficulty with word finding
- Headaches, often severe and treatment-resistant
- Tremors, numbness, or tingling sensations
- Vertigo and balance problems
Respiratory and Sinus Issues:
- Chronic sinus congestion and infections
- Shortness of breath and air hunger
- Cough that doesn't resolve with typical treatments
- Asthma-like symptoms or worsening of existing asthma
Musculoskeletal Symptoms:
- Joint pain and stiffness without arthritis diagnosis
- Muscle aches and cramping
- Morning stiffness lasting more than 30 minutes
- Ice-pick pains that move around the body
Energy and Temperature Regulation:
- Debilitating fatigue unrelieved by rest
- Night sweats and temperature dysregulation
- Excessive thirst and increased urination
- Unusual weight gain or difficulty losing weight
Gastrointestinal Symptoms:
- Abdominal pain and bloating
- Diarrhea or alternating bowel patterns
- Nausea and appetite changes
Visual and Sensory Changes:
- Blurred vision and light sensitivity
- Red or painful eyes
- Reduced visual contrast sensitivity (a key diagnostic marker)
- Metallic taste or unusual odors
Many CIRS patients describe feeling like they're "aging rapidly" or that their body is "falling apart" with no clear explanation. Symptoms typically worsen after being in water-damaged environments and may improve temporarily when away from the exposure source, though this pattern isn't universal.
The Diagnostic Process for CIRS
Diagnosing CIRS requires a systematic approach because no single test confirms the condition. The Shoemaker protocol uses a combination of clinical criteria, lab biomarkers, and visual testing to establish diagnosis.
Initial Screening Criteria:
- History of exposure to water-damaged buildings (confirmed by ERMI test, mycotoxin testing, or visual inspection)
- Symptoms matching at least 8 of 13 symptom clusters
- Visual Contrast Sensitivity (VCS) test showing abnormalities (available online for initial screening)
- Genetic susceptibility confirmed through HLA-DR testing
Essential Laboratory Biomarkers:
The diagnosis is strengthened by abnormalities in specific inflammatory markers that form a characteristic pattern. Key tests include:
- MMP-9 (Matrix Metallopeptidase 9) — typically elevated above 332 ng/mL, indicates ongoing inflammation
- TGF-beta 1 (Transforming Growth Factor Beta 1) — often elevated, promotes fibrosis and autoimmunity
- C4a complement — elevated above 2,830 ng/mL in most CIRS patients, indicates immune activation
- MSH (Melanocyte Stimulating Hormone) — typically low (below 35 pg/mL), affects multiple regulatory systems
- VEGF (Vascular Endothelial Growth Factor) — often low, causes poor blood flow and fatigue
- VIP (Vasoactive Intestinal Polypeptide) — frequently low, affects multiple systems including circulation
Additional tests may include ACTH, cortisol, ADH/osmolality, leptin, and inflammatory markers like C-reactive protein. Many CIRS patients also show evidence of multiple antibiotic-resistant coagulase-negative staphylococci (MARCoNS) in nasal passages, which perpetuates inflammation.
Diagnosis should be made by a physician trained in the Shoemaker protocol, as interpreting the biomarker pattern requires specialized knowledge. The Surviving Mold website maintains a directory of certified CIRS practitioners.
Treatment Protocol and Recovery Path
Treating CIRS requires a multi-step protocol that addresses biotoxin removal, inflammation reduction, and restoration of normal immune function. The Shoemaker protocol consists of 11-12 sequential steps that must be followed in order for optimal recovery.
Step 1: Remove from Exposure
No treatment will succeed if exposure continues. This means identifying and either remediating or leaving water-damaged environments. Professional assessment using ERMI testing or mycotoxin testing is essential. Many patients must temporarily relocate during remediation or permanently leave contaminated homes or workplaces.
Step 2: Bind and Remove Biotoxins
Cholestyramine (CSM), a prescription bile acid sequestrant, is the gold standard for binding mycotoxins and facilitating their removal. Standard dosing is 4 grams (one scoop) mixed in water four times daily, taken away from food and medications. Treatment typically continues for several months until MMP-9 and other inflammatory markers normalize. Alternative binders include Welchol (colesevelam) for those who cannot tolerate CSM.
Step 3: Eliminate MARCoNS
If present, multiple antibiotic-resistant staph in nasal passages must be eradicated using BEG nasal spray (Bactroban, EDTA, Gentamicin) compounded by specialty pharmacies. Treatment continues until nasal cultures are negative.
Step 4-11: Address Remaining Dysregulation
Subsequent steps target specific abnormalities revealed in lab work:
- Correcting MMP-9 elevation with omega-3 fatty acids (2.4g EPA+DHA daily) or low-dose statins
- Normalizing androgens if DHEA is low
- Correcting cortisol dysfunction
- Raising low VEGF with exercise rehabilitation
- Addressing persistent TGF-beta elevation
- Normalizing MSH with VIP nasal spray
- Treating exercise intolerance and pulmonary issues
Recovery Timeline:
Most patients see initial improvement within 1-3 months of starting cholestyramine, assuming exposure has been eliminated. Full recovery typically requires 6-18 months of treatment, though some patients with severe cases or continued low-level exposure may need longer. Regular retesting of biomarkers guides treatment progression and confirms recovery.
Success depends heavily on complete environmental elimination—patients who continue living or working in water-damaged buildings rarely achieve full recovery regardless of medical treatment.
Key Takeaways
- CIRS affects approximately 24% of the population who carry HLA gene variants preventing proper biotoxin elimination, causing chronic inflammation affecting multiple body systems simultaneously
- Diagnosis requires exposure history, symptoms from 8+ of 13 clusters, positive VCS test, HLA susceptibility, and characteristic lab abnormalities including elevated MMP-9, C4a, and low MSH
- The Shoemaker protocol involves 11-12 sequential treatment steps, with cholestyramine (4g four times daily) as the primary biotoxin binder, typically requiring several months of treatment
- Complete removal from water-damaged environments is mandatory—no medical treatment succeeds without eliminating ongoing exposure, often requiring remediation or relocation
- Recovery typically takes 6-18 months following the full protocol, with improvement beginning within 1-3 months of starting treatment if exposure is eliminated
- CIRS is often misdiagnosed as chronic fatigue syndrome, fibromyalgia, or multiple sclerosis due to overlapping symptoms and lack of awareness among conventional physicians
Frequently Asked Questions
Q: Can you have CIRS without the HLA gene susceptibility?
A: While the HLA-DR genetic susceptibility is present in approximately 95% of diagnosed CIRS patients, a small percentage (approximately 5%) develop CIRS through alternative immune pathways or particularly intense biotoxin exposure without the classic genetic markers. These cases are typically more responsive to treatment once the biotoxin source is eliminated.
Q: How is CIRS different from a mold allergy?
A: Mold allergies involve IgE-mediated immune responses causing typical allergy symptoms like sneezing, runny nose, and itchy eyes. CIRS involves a fundamentally different inflammatory cascade affecting multiple organ systems simultaneously, producing symptoms like chronic fatigue, cognitive impairment, joint pain, and hormonal disruption that extend far beyond allergic reactions.
Q: What tests are used to diagnose CIRS?
A: Diagnosis typically involves a combination of the Visual Contrast Sensitivity (VCS) test, blood biomarkers including C4a, TGF-beta-1, MSH, MMP-9, and VEGF, plus HLA-DR genetic testing. No single test is diagnostic—physicians use the pattern of multiple abnormal markers alongside clinical symptoms and documented biotoxin exposure.
Q: Can children develop CIRS?
A: Yes, children can develop CIRS and may be more vulnerable due to developing immune systems and higher relative exposure levels per body weight. Symptoms in children often manifest as behavioral changes, difficulty concentrating, recurring headaches, and unexplained fatigue, which are frequently misattributed to other conditions.
Q: Is CIRS curable or is it a lifelong condition?
A: With proper treatment following the Shoemaker Protocol—including removal from exposure, cholestyramine binding therapy, and correction of inflammatory markers—most patients achieve significant improvement or remission. However, re-exposure to water-damaged buildings can trigger relapse, making ongoing environmental awareness essential.